A Study on the Heterogeneous Effects of China’s Volume- Based Procurement on Gastrointestinal and Metabolic Medications
This study employs a multi-method approach to reveal that China's Volume-Based Procurement policy has exerted heterogeneous effects on the gastrointestinal and metabolic medication market, characterized by a drastic 82% decline in insulin sales versus a 50% growth in oral antidiabetics, with national policies and hospital channels demonstrating significantly stronger impacts than regional alliances and retail pharmacies.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine China's healthcare system as a massive, bustling marketplace where millions of people buy medicine every day. For years, the prices of these medicines were high, and the middlemen (distributors) were making huge profits. To fix this, the government introduced a policy called Volume-Based Procurement (VBP).
Think of VBP as a super-charged group-buying event. Instead of one hospital buying a few boxes of insulin, the government says, "We have 100 million patients who need this. If you, the drug company, want to sell to all of us, you must give us a massive discount." In exchange for that huge discount, the government guarantees the company a massive volume of sales.
This study looks at how this "group-buying" policy affected two specific aisles in the medicine marketplace: Gastrointestinal (stomach/digestion) and Metabolic (diabetes/blood sugar) drugs. The researchers found that the policy didn't hit every product the same way; it was like a storm that flattened some trees but only shook the leaves of others.
Here is a simple breakdown of what they found:
1. The "K-Shaped" Storm: Some Drugs Crashed, Some Soared
The researchers discovered that the policy created a "K-shaped" outcome (where one line goes down sharply, and another goes up).
- The Insulin Crash (The "Heavy" Drop):
Imagine insulin as a heavy, expensive anchor. When the government demanded a price cut, the sales of insulin dropped by a massive 82%.- Why? Insulin is an injection. Patients are often scared to switch brands because it involves needles and doctors' trust. Even though the price dropped, people didn't suddenly buy more of it to make up for the lower price. The "volume" didn't increase enough to save the revenue. It was a double hit: lower price + no extra sales.
- The Pill Boom (The "Light" Rise):
Now, imagine oral diabetes pills (like Metformin) as lightweight, easy-to-swallow items. When these got cheaper, their sales volume exploded.- Why? These pills are easy to switch between brands. When the price dropped, people bought way more of them. The "volume" increased so much that it actually made the total sales grow by 50%, even though the price per pill was lower. This is the "Volume-for-Price" success story.
2. The Two Doors: Hospital vs. Pharmacy
The study looked at where people bought these drugs: Hospitals (the main gate) and Retail Pharmacies (the side door).
- Hospitals are the "Epicenter":
Think of hospitals as the main stage where the policy is performed. When the government said "Buy this," hospitals immediately switched to the cheaper, winning brands. The change was instant and dramatic. - Pharmacies are the "Aftershock Zone":
Pharmacies were much slower to react. It's like a wave hitting a rock; the rock (hospital) feels the impact immediately, but the water (pharmacy) takes time to ripple out.- The Problem: Even though the drugs were cheaper in hospitals, patients couldn't easily take their prescriptions to the pharmacy to buy them. The "prescription outflow" (the ability to take a doctor's note to a store) is broken. So, pharmacies didn't see the same sales boost, and the price difference between hospitals and stores remained confusing.
3. The "Big Four" Categories: Who Won and Who Lost?
The researchers sorted the drugs into four groups to see who survived the storm:
- Insulin (The Losers): Suffered a massive sales drop. The "volume" didn't save them.
- Oral Diabetes Pills (The Winners): Sales grew because the lower price made people buy more.
- Liver & Digestion Drugs (The Survivors): These drugs (like those for liver disease) weren't the main target of the big group-buying deals. They were like sturdy trees in a forest fire; they barely felt the heat and kept growing steadily.
- New, Innovative Drugs (The Protected Ones): Drugs that are brand new and not yet on the "group-buying" list (like some new weight-loss or diabetes injections) were left alone. They grew explosively because they were the only options left that hadn't been forced to drop their prices.
4. The "Domestic Takeover"
Before this policy, big foreign companies (like Novo Nordisk or Sanofi) dominated the shelves. After the policy, it was like a musical chairs game where the foreign companies lost their seats.
- The Result: Chinese domestic companies, who could make the generic versions cheaper, took over the market share. The study found that for drugs like Acarbose (a diabetes pill), foreign brands lost huge chunks of their market, while local Chinese brands skyrocketed in sales.
5. The Bottom Line
The study concludes that the "Group-Buying" policy worked exactly as intended for the government: it slashed prices and saved money. However, it hit different drugs in different ways:
- Pills got a sales boost.
- Injections got a sales crash.
- Hospitals changed fast; Pharmacies are stuck in the slow lane.
- Local companies are winning; Foreign giants are losing ground.
The researchers suggest that for the policy to work even better, the government needs to fix the "side door" (pharmacies) so patients can actually use their cheaper prescriptions outside the hospital, and they need to be careful not to crush the prices of essential injections so hard that companies can't afford to keep making them.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.